TY  - GEN
AU  - Galiè,Nazzareno
AU  - Barberà,Joan A
AU  - Frost,Adaani E
AU  - Ghofrani,Hossein-Ardeschir
AU  - Hoeper,Marius M
AU  - McLaughlin,Vallerie V
AU  - Peacock,Andrew J
AU  - Simonneau,Gérald
AU  - Vachiery,Jean-Luc
AU  - Grünig,Ekkehard
AU  - Oudiz,Ronald J
AU  - Vonk-Noordegraaf,Anton
AU  - White,R James
AU  - Blair,Christiana
AU  - Gillies,Hunter
AU  - Miller,Karen L
AU  - Harris,Julia H N
AU  - Langley,Jonathan
AU  - Rubin,Lewis J
TI  - Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
SN  - 1533-4406
PY  - 2015///0904
KW  - Adult
KW  - Aged
KW  - Carbolines
KW  - adverse effects
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Drug Therapy, Combination
KW  - Female
KW  - Hospitalization
KW  - Humans
KW  - Hypertension, Pulmonary
KW  - drug therapy
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Natriuretic Peptide, Brain
KW  - blood
KW  - Peptide Fragments
KW  - Phenylpropionates
KW  - Pyridazines
KW  - Risk Factors
KW  - Tadalafil
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1056/NEJMoa1413687
ER  -